| Literature DB >> 31260937 |
Olivier Nuñez1, Bruno G Baldi2, Elżbieta Radzikowska3, Carlos R R Carvalho2, Carmen Herranz4, Malgorzata Sobiecka5, Olga Torre6, Sergio Harari6, Menno A M H Vergeer7, John Kolbe8, Marina Pollán9, Miquel Angel Pujana10.
Abstract
Lymphangioleiomyomatosis (LAM) is a rare metastasizing pulmonary disease that shares some clinical, cellular, and molecular similarities with metastatic breast cancer to lung. LAM cells have been identified circulating in various body fluids of patients and, intriguingly, diverse evidence indicates that these cells may originate from a different organ to the lung. Following on from these observations, we hypothesized the existence of a common risk basis between LAM and breast cancer, and suggested increased risk of breast cancer among LAM patients. Here, by studying two additional LAM cohorts with more detailed epidemiological, life-style, and disease-related data, we show consistent results; a potential excess of estrogen-receptor-positive young breast cancer cases in LAM. This observation further suggests the need of prospective studies to precisely assess the association between both diseases.Entities:
Keywords: Breast cancer; Estrogen receptor; Incidence; Lymphangioleiomyomatosis; Metastasis; mTOR
Mesh:
Year: 2019 PMID: 31260937 DOI: 10.1016/j.canep.2019.06.004
Source DB: PubMed Journal: Cancer Epidemiol ISSN: 1877-7821 Impact factor: 2.984